Natural history of untreated adult Immune Thrombocytopenia (ITP)
DOI:
https://doi.org/10.69898/jhtm.36.2026.282165Keywords:
Immune thrombocytopenia, ITP, natural course, prognostic factors, untreated ITPAbstract
Background: International guidelines recommend that patients with Immune thrombocytopenia (ITP) presenting platelets > 30x109/L should be followed-up without treatment. However, data on clinical courses and risk factors are limited.
Objective: To determine the natural history and prognostic factors of untreated ITP.
Materials and Methods: This retrospective cohort included adult ITP patients (platelet count 30-149 x109/L) at King Chulalongkorn Memorial Hospital from January 2015 to October 2022. Treatments were provided only to patients with platelet counts < 30x109/L and/or major bleeding.
Results: A total of 73 patients were included. The mean age was 62 ± 16.64 years, and 56% were female. The median follow-up time was 3 years, comprising 272.48 patient-years. Seventeen patients (23.3%) subsequently required treatments, with an incidence rate of 6.24% per year (95% Confidence interval [CI], 3.88-10.0%). In multivariate analysis, risk factors for requiring treatment were age < 35 years (adjusted hazard ratio [aHR] 3.93; 95%CI, 1.27-12.22, P = 0.018) and a maximum-minimum platelet count during follow-up (excluding counts at treatment initiation) ≥ 70x109/L (aHR 2.89; 95%CI, 1.02-8.23, P = 0.047). Baseline platelet count did not predict outcomes, but persistently maintaining platelet counts >100 x 109/L for more than 3 or 6 months was associated with better prognosis. No severe bleeding related to thrombocytopenia was observed. The spontaneous recovery rate was 10% with an incidence of 2.57% per year (95%CI, 1.22-5.93%).
Conclusions: The majority of untreated ITP patients had a good prognosis. Adverse risk factors included younger age and wide fluctuations in platelet counts.
Downloads
References
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168-86. https://doi-org.cuml1.md.chula.ac.th/10.1182/blood-2009-06-225565.
Singh A, Uzun G, Bakchoul T. Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. J Clin Med 2021;10:1-21. https://doi.org/10.3390/jcm10040789.
Semple JW, Rebetz J, Maouia A, Kapur R. An update on the pathophysiology of immune thrombocytopenia. Curr Opin Hematol 2020;27:423-9. https://doi.org/10.1097/MOH.0000000000000612.
Cooper N, Ghanima W. Immune thrombocytopenia. The New England journal of medicine 2019;10:945-55. https://doi.org/10.1056/NEJMcp1810479.
Arnold DM. Bleeding complications in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2015;2015:237-42. https://doi.org/10.1182/asheducation-2015.1.237.
Kohli R, Chaturvedi S. Epidemiology and Clinical manifestations of immune thrombocytopenia. Hamostaseologie 2019;3:239-249. https://doi.org/ 10.1055/s-0039-1683416.
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American society of hematology 2019 guidelines for immune thrombocytopenia. Blood Advances 2019;3:3829-3866. https://doi.org/10.1182/bloodadvances.2019000966.
Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, Ghanima W, Arnold DM, Tomiyama Y, Santoro C, Michel M, Laborde S, Lovrencic B, Hou M, Bailey T, Taylor-Stokes G, Haenig J, Bussel JB. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hematol. 2021;96:199-207. https://doi.org/10.1002/ajh.26036.
Cooper N, Cuker A, Bonner N, Ghanima W, Provan D, Morgan M, Taylor B, D'Alessio D, Arnold D, Viana R. Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). Br J Haematol 2021;194:59-766. https://doi.org/10.1111/bjh.17694.
Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, O'Malley BA, Sesok-Pizzini DA, Shander A, Stack GE, Webert KE, Weinstein R, Welch BG, Whitman GJ, Wong EC, Tobian AA; AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162:205-13.
Schmidt DE, Wendtland Edslev P, Heitink-Pollé KMJ, Mertens B, Bruin MCA, Kapur R, et al. A clinical prediction score for transient versus persistent childhood immune thrombocytopenia. J Thromb Haemost. 2021;19:121-130. https://doi.org/10.1111/ jth.15125.
Bizzoni L, Mazzucconi MG, Gentile M, Santoro C, Bernasconi S, Chiarotti F, et al. Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. European journal hematology 2006;76:210-216. https://doi.org/10.1111/j.1600-0609.2005.00602.x.
Stasi R, Stipa E, Masi M, Cecconi M, Terese M, Oliva F, et al. Long term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. The American journal of medicine 1995;98:436-442. https://doi.org/10.1016/S0002-9343(99)80342-8.
Kueh YK. Adult idiopathic thrombocytopenic purpura (ITP) – A prospective tracking of its natural history. Singapore Med J 1995;36:367-370.
Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia. PLOS MEDICINE 2006;3:388-394. https://doi.org/10.1371/journal.pmed.0030024.
Ayad N, Grace RF, Kuter DJ, Al-Samkari H. Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. Blood 2022;140:2849-2852. https://doi.org/10.1182/blood.2022016757
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
